Epigenetic modifications in muscle regeneration and progression of Duchenne muscular dystrophy

Clin Epigenetics. 2021 Jan 19;13(1):13. doi: 10.1186/s13148-021-01001-z.

Abstract

Duchenne muscular dystrophy (DMD) is a multisystemic disorder that affects 1:5000 boys. The severity of the phenotype varies dependent on the mutation site in the DMD gene and the resultant dystrophin expression profile. In skeletal muscle, dystrophin loss is associated with the disintegration of myofibers and their ineffective regeneration due to defective expansion and differentiation of the muscle stem cell pool. Some of these phenotypic alterations stem from the dystrophin absence-mediated serine-threonine protein kinase 2 (MARK2) misplacement/downregulation in activated muscle stem (satellite) cells and neuronal nitric oxide synthase loss in cells committed to myogenesis. Here, we trace changes in DNA methylation, histone modifications, and expression of regulatory noncoding RNAs during muscle regeneration, from the stage of satellite cells to myofibers. Furthermore, we describe the abrogation of these epigenetic regulatory processes due to changes in signal transduction in DMD and point to therapeutic treatments increasing the regenerative potential of diseased muscles based on this acquired knowledge.

Keywords: Duchenne muscular dystrophy (DMD); Epigenetics; Muscle regeneration; Pathways; Satellite cells; Signaling.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • DNA Methylation*
  • Disease Progression
  • Dystrophin / genetics*
  • Epigenesis, Genetic*
  • Gene Expression Regulation
  • Genetic Therapy*
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Muscle, Skeletal / growth & development*
  • Muscular Dystrophy, Duchenne / genetics*
  • Muscular Dystrophy, Duchenne / physiopathology*
  • Muscular Dystrophy, Duchenne / therapy
  • Mutation
  • Phenotype
  • Regeneration / genetics*
  • Young Adult

Substances

  • Dystrophin